Found 5 clinical trials
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
agalsidase beta (FABRAZYME). In contrast, no randomized, controlled study of the efficacy of recombinant alpha-galactosidase A has been reported in heterozygotes for Fabry disease.
- 31 views
- 07 Nov, 2020
- 1 location
China Post-marketing Surveillance (PMS) Study of Fabrazyme®
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with
- 0 views
- 05 Nov, 2021
- 1 location
China Post-marketing Surveillance (PMS) Study of Fabrazyme
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with
- 0 views
- 09 Nov, 2021
- 1 location
Fabry Disease Registry & Pregnancy Sub-registry
(such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global
- 456 views
- 22 Oct, 2021
- 563 locations
Fabry Disease Registry & Pregnancy Sub-registry
(such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global
- 0 views
- 05 Nov, 2021
- 250 locations